Trinity Biotech ROE 2010-2024 | TRIB
Current and historical return on equity (ROE) values for Trinity Biotech (TRIB) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Trinity Biotech ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-09-30 | $-0.02B | $-0.03B | 82.35% |
| 2024-06-30 | $-0.02B | $-0.03B | 98.92% |
| 2024-03-31 | $-0.02B | $-0.02B | 117.33% |
| 2023-12-31 | $-0.03B | $-0.02B | 169.49% |
| 2023-09-30 | $-0.03B | $-0.02B | 313.51% |
| 2023-06-30 | $-0.03B | $-0.01B | 953.85% |
| 2023-03-31 | $-0.04B | $-0.01B | -1000.00% |
| 2022-12-31 | $-0.04B | $0.00B | -1093.33% |
| 2022-09-30 | $-0.03B | $0.01B | -752.94% |
| 2022-06-30 | $-0.02B | $0.02B | -800.00% |
| 2022-03-31 | $-0.01B | $-0.01B | 1040.00% |
| 2021-12-31 | $0.00B | $0.00B | 400.00% |
| 2021-09-30 | $-0.01B | $0.00B | 3200.00% |
| 2021-06-30 | $0.00B | $0.00B | -160.00% |
| 2021-03-31 | $0.00B | $0.00B | -200.00% |
| 2020-12-31 | $-0.01B | $0.00B | -480.00% |
| 2020-09-30 | $-0.02B | $0.01B | -633.33% |
| 2020-06-30 | $-0.03B | $0.00B | -236.36% |
| 2020-03-31 | $-0.03B | $0.00B | -142.86% |
| 2019-12-31 | $-0.03B | $0.01B | -88.19% |
| 2019-09-30 | $-0.03B | $0.04B | -69.88% |
| 2019-06-30 | $-0.03B | $0.04B | -57.44% |
| 2019-03-31 | $-0.02B | $0.04B | -39.46% |
| 2018-12-31 | $-0.02B | $0.04B | -35.92% |
| 2018-09-30 | $-0.04B | $0.07B | -61.65% |
| 2018-06-30 | $-0.04B | $0.07B | -55.26% |
| 2018-03-31 | $-0.04B | $0.07B | -48.84% |
| 2017-12-31 | $-0.04B | $0.07B | -42.38% |
| 2017-09-30 | $-0.10B | $0.11B | -91.88% |
| 2017-06-30 | $-0.10B | $0.11B | -74.77% |
| 2017-03-31 | $-0.10B | $0.11B | -61.97% |
| 2016-12-31 | $-0.10B | $0.11B | -54.45% |
| 2016-09-30 | $0.00B | $0.21B | 1.42% |
| 2016-06-30 | $0.02B | $0.21B | 7.55% |
| 2016-03-31 | $0.02B | $0.21B | 8.08% |
| 2015-12-31 | $0.02B | $0.21B | 10.59% |
| 2015-09-30 | $0.02B | $0.21B | 11.30% |
| 2015-06-30 | $0.02B | $0.21B | 7.52% |
| 2015-03-31 | $0.02B | $0.20B | 8.11% |
| 2014-12-31 | $0.02B | $0.20B | 8.24% |
| 2014-09-30 | $0.02B | $0.20B | 8.91% |
| 2014-06-30 | $0.01B | $0.20B | 5.38% |
| 2014-03-31 | $0.01B | $0.19B | 5.54% |
| 2013-12-31 | $0.01B | $0.18B | 5.65% |
| 2013-09-30 | $0.01B | $0.18B | 5.19% |
| 2013-06-30 | $0.02B | $0.18B | 9.36% |
| 2013-03-31 | $0.02B | $0.18B | 9.57% |
| 2012-12-31 | $0.02B | $0.17B | 9.80% |
| 2012-09-30 | $0.02B | $0.17B | 10.08% |
| 2012-06-30 | $0.02B | $0.16B | 10.34% |
| 2012-03-31 | $0.02B | $0.16B | 10.56% |
| 2011-12-31 | $0.02B | $0.15B | 10.81% |
| 2011-09-30 | $0.02B | $0.15B | 11.00% |
| 2011-06-30 | $0.02B | $0.15B | 10.53% |
| 2011-03-31 | $0.06B | $0.15B | 44.60% |
| 2010-12-31 | $0.06B | $0.14B | 49.49% |
| 2010-09-30 | $0.06B | $0.14B | 55.68% |
| 2010-06-30 | $0.06B | $0.13B | 64.86% |
| 2010-03-31 | $0.01B | $0.08B | 15.53% |
| 2009-12-31 | $0.01B | $0.08B | 16.33% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.010B | $0.057B |
| Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $227.162B | 27.40 |
| Boston Scientific (BSX) | United States | $140.689B | 37.90 |
| Stryker (SYK) | United States | $132.255B | 28.42 |
| EssilorLuxottica (ESLOY) | France | $128.431B | 0.00 |
| Medtronic (MDT) | Ireland | $105.938B | 15.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.424B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.151B | 26.20 |
| ResMed (RMD) | United States | $31.269B | 24.08 |
| Agilent Technologies (A) | United States | $29.217B | 19.30 |
| GE HealthCare Technologies (GEHC) | United States | $28.556B | 13.89 |
| Terumo (TRUMY) | Japan | $28.160B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.192B | 15.85 |
| Zimmer Biomet Holdings (ZBH) | United States | $19.373B | 12.24 |
| Insulet (PODD) | United States | $17.332B | 74.11 |
| Baxter (BAX) | United States | $14.818B | 10.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.356B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.938B | 17.06 |
| Bio-Rad Laboratories (BIO) | United States | $6.672B | 23.10 |
| Demant (WILYY) | Denmark | $6.644B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.977B | 18.98 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.455B | 9.89 |
| ICU Medical (ICUI) | United States | $3.400B | 29.07 |
| Haemonetics (HAE) | United States | $2.872B | 13.52 |
| Envista Holdings (NVST) | United States | $2.614B | 20.80 |
| GN Store Nord (GNNDY) | Denmark | $2.188B | 14.75 |
| LeMaitre Vascular (LMAT) | United States | $1.946B | 44.47 |
| QuidelOrtho (QDEL) | United States | $1.698B | 14.22 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.214B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.189B | 18.67 |
| AdaptHealth (AHCO) | United States | $1.051B | 10.12 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| InMode (INMD) | Israel | $1.038B | 8.67 |
| Neogen (NEOG) | United States | $0.953B | 12.19 |
| Phibro Animal Health (PAHC) | United States | $0.700B | 10.74 |
| Evolus (EOLS) | United States | $0.686B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.649B | 0.00 |
| Valneva SE (VALN) | France | $0.552B | 0.00 |
| Owens & Minor (OMI) | United States | $0.535B | 4.56 |
| CeriBell (CBLL) | United States | $0.532B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.514B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.453B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.450B | 0.00 |
| Surmodics (SRDX) | United States | $0.394B | 0.00 |
| Omeros (OMER) | United States | $0.394B | 0.00 |
| SNDL (SNDL) | Canada | $0.368B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.302B | 13.07 |
| Viemed Healthcare (VMD) | United States | $0.262B | 23.68 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 15.65 |
| Sanuwave Health (SNWV) | United States | $0.256B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.251B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.250B | 44.40 |
| Cerus (CERS) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.200B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Biote (BTMD) | United States | $0.181B | 4.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.175B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.24 |
| Brainsway (BWAY) | Israel | $0.155B | 48.47 |
| Jin Medical (ZJYL) | China | $0.147B | 0.00 |
| Organigram Global (OGI) | Canada | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.42 |
| Agape ATP (ATPC) | $0.094B | 0.00 | |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.086B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.083B | 0.00 |
| Exagen (XGN) | United States | $0.080B | 0.00 |
| MacroGenics (MGNX) | United States | $0.079B | 0.00 |
| Veru (VERU) | United States | $0.078B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.65 |
| Zynex (ZYXI) | United States | $0.066B | 24.22 |
| United Health Products (UEEC) | United States | $0.065B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 11.61 |
| Apyx Medical (APYX) | United States | $0.037B | 0.00 |
| Modular Medical (MODD) | United States | $0.036B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 51.50 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |